Alaunos Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
TCRT$1.71+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows for the Years Ended
CASH FLOWS
(in thousands)
| For the years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(4,176) | $(4,679) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 7 | 2 |
| Change in fair value of warrant liability | 31 | — |
| Common stock issued for services rendered | 382 | — |
| Stock-based compensation | 414 | 435 |
| Changes in operating assets and liabilities: | ||
| Receivables | 2 | (4) |
| Prepaid expenses and other current assets | 350 | 539 |
| Accounts payable | 97 | (100) |
| Accrued expenses | 24 | (1,164) |
| Net cash flows from operating activities | (2,869) | (4,971) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (98) | — |
| Net cash flows from investing activities | (98) | — |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock and pre funded warrants, net of offering costs | 1,911 | — |
| Proceeds from sale of Series A-1 preferred stock | 500 | — |
| Proceeds from sale of Series A-2 preferred stock | 850 | — |
| Net cash flows from financing activities | 3,261 | — |
| Net increase (decrease) in cash, cash equivalents | 294 | (4,971) |
| Cash and cash equivalents, beginning of period | 1,091 | 6,062 |
| Cash and cash equivalents, end of period | $1,385 | $1,091 |
| Supplementary disclosure of cash flow information: | ||
| Cash paid for interest | $— | $— |
| Noncash financing activities: | ||
| Recognition of warrant liability in connection with the equity line of credit agreement | $178 | $— |
| Amounts included in accrued expenses and accounts payable related to property and equipment | $67 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.